Welcome
Support Centre
11 February 2012 
ISRCTN Register - International Standard Randomized Controlled Trial Number
Trial registration
Unique identification scheme
International databases
home  |   my details  |   ISRCTN Register  |   mRCT  |   links  |   information  |   press
Find trials
ISRCTN Register
tips on searching

Registration
New application
Updating record

Information
introduction
governing board
ISRCTN FAQs
data set
letter of agreement
request information
guidance notes

[ Print-friendly version ]
The analgesic effect of parecoxib following total abdominal hysterectomy
ISRCTN ISRCTN47655040
ClinicalTrials.gov identifier
Public title The analgesic effect of parecoxib following total abdominal hysterectomy
Scientific title
Acronym N/A
Serial number at source N0123138268
Study hypothesis To investigate the analgesic effects and benefits of parecoxib.
Lay summary
Ethics approval Not provided at time of registration
Study design Randomised controlled trial
Countries of recruitment United Kingdom
Disease/condition/study domain Post-operative pain
Participants - inclusion criteria 1. Patients having total abdominal hysterectomy
2. American Society of Anesthesiologists (ASA) 1-11
3. Aged 20 - 65, female
Participants - exclusion criteria 1. Patients having hysterectomy/morphine consumption
2. Pain
3. Sedation
4. Nausea
Anticipated start date 15/05/2002
Anticipated end date 01/04/2003
Status of trial Completed
Patient information material
Target number of participants 21 controls/21 patients
Interventions All patients were given intraoperative:
1. Propofol 2 - 4 mg kg intravenously (i.v.)
2. Morphine 10 mg i.v.
3. Prochlorperazine 12.5 mg intramuscularly (i.m.)

Patients' lungs were ventilated with nitrous oxide and isoflurane 1 - 1.5% in oxygen, and morphine was self-administered for postoperative analgesia via a patient controlled analgesia (PCA) device.

Patients were allocated randomly to receive either parecoxib 40 mg i.v. or normal saline on induction of anaesthesia.
Primary outcome measure(s) 1. Morphine consumption
2. Pain
3. Sedation
4. Nausea
Secondary outcome measure(s) Not provided at time of registration
Sources of funding 1. University Hospitals of Leicester NHS Trust (UK)
2. Departmental funding
Trial website
Publications Results in http://www.ncbi.nlm.nih.gov/pubmed/12765890
Contact name Dr  A  Ng
  Address University Hospitals of Leicester
University Hospitals of Leicester
c/o Research and Development Office
Leicester General Hospital NHS Trust
  City/town Leicester
  Zip/Postcode LE1 4PW
  Country United Kingdom
Sponsor Record Provided by the NHSTCT Register - 2005 Update - Department of Health (UK)
  Address The Department of Health
Richmond House
79 Whitehall
  City/town London
  Zip/Postcode SW1A 2NL
  Country United Kingdom
  Tel +44 (0)20 7307 2622
  Fax +44 (0)20 7307 2623
  Email dhmail@doh.gsi.org.uk
  Sponsor website: http://www.dh.gov.uk/Home/fs/en
Date applied 30/09/2005
Last edited 14/04/2008
Date ISRCTN assigned 30/09/2005
Submit your trial protocol
Submit to Trials journal
Follow us on Twitter
© 2012 ISRCTN unless otherwise stated.


BioMed Central